Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns

Overview

• Pfizer has voluntarily recalled its sickle cell disease treatment Oxbryta globally due to safety concerns linked to severe pain crises and fatalities.
• The European Medicines Agency disclosed 16 deaths in clinical trials, leading to the suspension of Oxbryta's marketing authorization in Europe.
• The FDA is conducting a safety review of postmarketing clinical data and real-world registry studies to assess the risks associated with Oxbryta.
• The withdrawal is expected to accelerate trials of rival sickle cell treatments, with companies like Agios Pharmaceuticals and Fulcrum Therapeutics seeing a boost in their stock prices.
• Pfizer's move comes amid broader challenges for the company, including declining sales of its COVID-19 products and a disappointing launch of its RSV vaccine.